DCT
3:26-cv-12469
Opus Genetics Inc v. Sandoz Inc
Key Events
Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Opus Genetics, Inc. (Delaware) and FamyGen Life Sciences, Inc. (Nevada)
- Defendant: Sandoz Inc. (Delaware)
- Plaintiff’s Counsel: Duane Morris LLP
- Case Identification: 3:26-cv-12469, D.N.J., 09/21/2026
- Venue Allegations: Venue is based on Defendant Sandoz Inc.’s regular and established place of business in Princeton, New Jersey, where acts of infringement, including the submission of the Abbreviated New Drug Application (ANDA), are alleged to have occurred. Plaintiffs also note that Sandoz has previously consented to personal jurisdiction and venue in the district in prior related litigation.
- Core Dispute: Plaintiffs allege that Defendant’s submission of an ANDA seeking FDA approval to market a generic version of Plaintiffs' RYZUMVI® ophthalmic solution constitutes an act of patent infringement under the Hatch-Waxman Act.
- Technical Context: The technology relates to pharmaceutical formulations of aqueous ophthalmic solutions containing phentolamine, which are used for medical purposes such as reversing pharmacologically-induced pupil dilation (mydriasis).
- Key Procedural History: The complaint states this is the third lawsuit filed by Plaintiffs against Sandoz concerning the same ANDA (No. 219888). Two prior suits, filed in March 2025 and April 2026, asserted different patents against the same proposed generic product. This action follows the issuance of the two patents-in-suit in September 2026.
Case Timeline
| Date | Event |
|---|---|
| 2013-02-01 | Earliest Priority Date for ’810 and ’126 Patents |
| 2023-09-25 | FDA Approval of RYZUMVI® New Drug Application |
| 2025-01-31 | Sandoz's First Notice Letter sent to Plaintiffs |
| 2025-02-27 | Sandoz's Second Notice Letter sent to Plaintiffs |
| 2025-03-14 | First related lawsuit filed (No. 3:25-cv-1895) |
| 2026-04-29 | Second related lawsuit filed (No. 3:26-cv-04811) |
| 2026-09-01 | U.S. Patent No. 12,721,810 Issued |
| 2026-09-15 | U.S. Patent No. 12,734,126 Issued |
| 2026-09-21 | Complaint Filed in Present Action |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 12,721,810 - Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
- Patent Identification: U.S. Patent No. 12,721,810, "Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof," issued September 1, 2026 Compl. ¶21
The Invention Explained
- Problem Addressed: The patent's background section describes the difficulty in creating stable, aqueous formulations of phentolamine salts for ophthalmic use without employing a chelating agent, such as EDTA, which was believed to be necessary to maintain stability ʼ810 Patent, col. 1:55-62
- The Patented Solution: The invention provides stable, aqueous ophthalmic solutions of phentolamine that are explicitly "free of a chelating agent" ʼ810 Patent, col. 2:1-2 Stability is achieved through a specific combination of phentolamine (or its salt), at least one polyol compound (e.g., mannitol), a buffer, and water, all maintained within a particular pH range ʼ810 Patent, abstract ʼ810 Patent, col. 2:29-38 This formulation is designed to be well-suited for administration as an eye drop and to minimize the stinging sensation associated with some prior art solutions ʼ810 Patent, col. 2:23-28
- Technical Importance: The invention provided a path to a stable and comfortable ophthalmic phentolamine formulation that avoids chelating agents, which were previously considered essential for the stability of such solutions ʼ810 Patent, col. 1:55-62 ʼ810 Patent, col. 2:1-9
Key Claims at a Glance
The complaint alleges infringement of "at least one claim" without specifying which claims are asserted Compl. ¶35 Independent claim 1 is a representative method-of-making claim.
- Independent Claim 1: A method of making an aqueous ophthalmic solution, the essential steps of which are:
- combining:
- phentolamine or a pharmaceutically acceptable salt thereof at a concentration of about 0.1% to 4% (w/v);
- at least one polyol compound selected from a specific group (e.g., mannitol, glycerol);
- at least one buffer at a concentration of about 0.1 mM to 10 mM; and
- water;
- wherein the resulting solution does not contain an additional ingredient that is a chelating agent; and
- wherein the resulting solution does not contain an additional ingredient that is a stabilizer ʼ810 Patent, col. 42:1-20
- combining:
U.S. Patent No. 12,734,126 - Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
- Patent Identification: U.S. Patent No. 12,734,126, "Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof," issued September 15, 2026 Compl. ¶24
The Invention Explained
- Problem Addressed: As with the ʼ810 Patent, the background identifies the need for stable ophthalmic phentolamine formulations that do not require a chelating agent ʼ126 Patent, col. 1:55-62
- The Patented Solution: This patent claims a method of using the chelator-free phentolamine formulation to achieve a therapeutic effect. Specifically, it claims a method of pupil reduction that involves storing the specific formulation at a controlled temperature and then administering it to a patient's eye ʼ126 Patent, abstract ʼ126 Patent, col. 43:4-31
- Technical Importance: The invention secures patent protection for the specific therapeutic application of the stable, chelator-free phentolamine formulation, a key element for protecting a branded drug's market exclusivity ʼ126 Patent, col. 2:38-46
Key Claims at a Glance
The complaint alleges infringement of "at least one claim" without further specification Compl. ¶53 Independent claim 1 is a representative method-of-use claim.
- Independent Claim 1: A method of pupil reduction, the essential steps of which are:
- storing an aqueous ophthalmic solution at a temperature in the range of 2-8° C.;
- administering that solution to the eye of a patient;
- wherein the solution comprises phentolamine, a polyol, a buffer, and water, within specified concentrations;
- wherein the solution does not contain an additional ingredient that is a chelating agent;
- wherein the solution does not contain an additional ingredient that is a stabilizer; and
- wherein the solution has a pH of about 4.0 to 7.5 ʼ126 Patent, col. 43:4-31
III. The Accused Instrumentality
Product Identification
- The accused instrumentality is "Sandoz's ANDA Product," identified as a proposed generic version of RYZUMVI® (phentolamine ophthalmic solution, 0.75%) for which Sandoz filed ANDA No. 219888 Compl. ¶1
Functionality and Market Context
- The complaint alleges that Sandoz's ANDA Product is intended to be a generic version of RYZUMVI® and is represented to the FDA as "pharmaceutically and therapeutically equivalent" Compl. ¶33 Compl. ¶51 RYZUMVI® is a sterile ophthalmic solution indicated for the treatment of pharmacologically-induced mydriasis Compl. ¶¶18-19 Plaintiffs allege that Sandoz's product has a label and indications that are "the same, or substantially the same, as RYZUMVI®" Compl. ¶29 This equivalence forms the basis for the infringement allegations, as the proposed generic product is expected to possess the same formulation characteristics and be used in the same manner as the branded drug.
IV. Analysis of Infringement Allegations
The complaint provides a high-level notice of infringement without detailed factual allegations mapping specific features of the accused product to the claim elements. This is characteristic of initial complaints in ANDA litigation filed before the plaintiff has received the confidential ANDA materials through discovery. No probative visual evidence provided in complaint.
U.S. Patent No. 12,721,810 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of making an aqueous ophthalmic solution, the method comprising combining: a. phentolamine or a pharmaceutically acceptable salt thereof... b. at least one polyol compound... c. at least one buffer... d. water; | The complaint does not provide sufficient detail for analysis. It alleges infringement based on Sandoz’s submission of its ANDA, which seeks approval to manufacture and sell a generic version of RYZUMVI® (the "ANDA Product"). | ¶35; ¶46 | col. 42:1-12 |
| provided the aqueous ophthalmic solution does not contain any additional ingredient that is a chelating agent, and wherein the aqueous ophthalmic solution does not contain any additional ingredient that is a stabilizer. | The complaint does not provide sufficient detail for analysis of the specific excipients in Sandoz's ANDA Product. The infringement theory relies on the product being a generic equivalent of the patented formulation. | ¶29; ¶33 | col. 42:13-20 |
U.S. Patent No. 12,734,126 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of pupil reduction comprising administering to a subject an effective amount of an aqueous ophthalmic solution, wherein said method comprises: (a) storing said aqueous ophthalmic solution at temperature in the range of 2-8° C.; and (b) administrating said aqueous ophthalmic solution to the eye of a patient... | The complaint does not provide sufficient detail for analysis. The infringement allegation is based on the assertion that Sandoz’s ANDA Product will have a label that instructs users to perform the patented method, as its label and indications will be the same or substantially the same as RYZUMVI®. | ¶29; ¶55; ¶64 | col. 43:4-13 |
| wherein said aqueous ophthalmic solution comprises: a. about 0.1% (w/v) to about 4% (w/v) of phentolamine...b. at least one polyol compound... c. about 0.1 mM to about 10 mM of at least one buffer...d. water; ... and wherein said aqueous ophthalmic solution has a pH of about 4.0 to 7.5. | The complaint does not provide sufficient detail for analysis of the specific formulation in Sandoz's ANDA. It alleges the ANDA Product is "pharmaceutically and therapeutically equivalent" to RYZUMVI®, implying its formulation will meet the claimed parameters. | ¶29; ¶51 | col. 43:14-31 |
| provided the aqueous ophthalmic solution does not contain any additional ingredient that is a chelating agent, and wherein the aqueous ophthalmic solution does not contain any additional ingredient that is a stabilizer... | The complaint does not provide sufficient detail for analysis of the specific excipients. The infringement theory presumes Sandoz's formulation will be free of these specific agent types to achieve bioequivalence with RYZUMVI®. | ¶29; ¶51 | col. 43:21-25 |
- Identified Points of Contention:
- Scope Questions: A central dispute for both patents will concern the negative limitations. What is the scope of the terms "chelating agent" and "stabilizer"? A court will have to determine whether an excipient with a primary purpose other than chelating or stabilizing (e.g., an antioxidant or buffer) but with incidental chelating or stabilizing properties would fall within the exclusion, thereby allowing Sandoz to argue non-infringement.
- Technical Questions: For the ʼ810 Patent, a key factual question will be what manufacturing process is described in Sandoz's confidential ANDA. Does that process meet the "combining" limitation of claim 1? For the ʼ126 Patent, the analysis will focus on Sandoz's proposed product label. Does the label instruct storage at "2-8° C." as required by claim 1? Does the formulation described in the ANDA meet the claimed compositional and pH parameters?
V. Key Claim Terms for Construction
The Term: "chelating agent"
Context and Importance: This negative limitation is fundamental to the patents' assertion of novelty over prior art that required chelators for stability. The entire infringement case may depend on whether Sandoz's ANDA product is "free of a chelating agent." Practitioners may focus on this term because Sandoz could argue that an excipient in its formulation has some chelating functionality, thus avoiding infringement.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation (Plaintiff-friendly): The specification explicitly identifies "disodium ethylenediaminetetraacetic acid (EDTA)" as an example of a chelating agent that the invention avoids '810 Patent, col. 1:57-59 Plaintiffs may argue this contextualizes "chelating agent" as a term of art referring to strong, conventional chelators added for that express purpose, not any compound with incidental chelating properties.
- Evidence for a Narrower Interpretation (Defendant-friendly): The patents do not provide an explicit definition of "chelating agent." A defendant may argue for a broad, functional definition encompassing any compound that complexes with metal ions, regardless of its primary purpose or strength. They could then point to an excipient in their formulation and argue it performs this function to some degree.
The Term: "stabilizer"
Context and Importance: The independent claims of both patents require that the solution "does not contain any additional ingredient that is a stabilizer" '810 Patent, col. 42:19-20 '126 Patent, col. 43:24-25 This term's definition is critical, as Sandoz could design its formulation with an excipient it argues is a "stabilizer" to circumvent the claims.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation (Plaintiff-friendly): Plaintiffs may argue that since the claims positively require a polyol and a buffer—which themselves provide stability—the negative limitation must refer to a different, third-party stabilizer not already recited in the claim. The use of "additional ingredient" may support this reading.
- Evidence for a Narrower Interpretation (Defendant-friendly): The specification itself describes "polyols, such as mannitol," as "stabilizing agents" '810 Patent, col. 14:52-54 A defendant could argue this creates ambiguity: if a required ingredient (the polyol) is a stabilizer, what does it mean for the solution to not contain a stabilizer? This could be a basis for an indefiniteness argument or a construction that reads on any formulation with an ingredient that has a stabilizing effect.
VI. Other Allegations
- Indirect Infringement: The complaint alleges that upon approval of its ANDA, Sandoz will induce infringement of the patents-in-suit Compl. ¶46 Compl. ¶64 The factual basis for this allegation is that Sandoz's proposed product label will be the same or substantially the same as the RYZUMVI® label, thereby instructing medical professionals and patients to use the generic product in an infringing manner Compl. ¶29
- Willful Infringement: While the complaint does not use the term "willful," it lays the foundation for such a claim by alleging Sandoz has "actual knowledge" of the patents, at least as of their issuance dates Compl. ¶34 Compl. ¶52 Plaintiffs also request a finding that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285, which is the standard procedural step for preserving a potential willfulness argument Compl. ¶41 Compl. ¶59 Compl., prayer F
VII. Analyst’s Conclusion: Key Questions for the Case
- A core issue will be one of definitional scope: how will the court construe the negative limitations "chelating agent" and "stabilizer"? The viability of Sandoz's potential non-infringement defense may turn on whether an excipient with incidental or secondary chelating or stabilizing properties falls within the scope of these excluded categories.
- A second key issue will be one of label-based infringement: for the method-of-use claims in the ʼ126 Patent, does the storage information and other instructions on Sandoz's proposed ANDA label direct users to perform all steps of the asserted claims, including the "storing...at...2-8° C." limitation?
- A third determinative question will be evidentiary and factual: for the method-of-making claims in the ʼ810 Patent, what specific manufacturing process is outlined in Sandoz’s confidential ANDA filing? An analysis of that undisclosed process will be required to determine if it meets the "combining" and compositional elements of the asserted claims.
Analysis metadata